Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P455: Clinical features of tuberculosis infection in inflammatory bowel disease patients on anti-TNF therapyECCO '17 Barcelona
Year: 2017
Authors:

Estévez-Gil M.1, De Castro M.L.*2, Hernández V.2, Pineda J.R.2, Martínez-Cadilla J.2, Pereira S.2, Rodríguez-Prada J.-I.2

1Hospital Alvaro Cunqueiro, Complexo Hospitalario Universitario de Vigo, Instituto de Investigaciόn Biomédica, Medicine, Vigo, Spain 2Hospital Alvaro Cunqueiro, Complexo Hospitalario Universitario de Vigo, Instituto de Investigaciόn Biomédica, Gastroenterology, Vigo, Spain

P456: Comparative analysis of oral versus intravenous iron in patients with inflammatory bowel disease and iron deficiency/anaemia – impact on hospitalisation in GermanyECCO '17 Barcelona
Year: 2017
Authors:

Borchert K.1, Hardt T.2, Haas J.S.1, Ong S.H.3, Lechat E.1, Nip K.2, Foerster D.3, Braun S.1, Stein J.*4,5

1Xcenda GmbH, Hannover, Germany 2Vifor Pharma Deutschland GmbH, Munich, Germany 3Vifor Pharma Ltd., Glattbrugg, Switzerland 4Interdisciplinary Crohn Colitis Centre Rhein-Main, Frankfurt/Main, Germany 5DGD Clinics Sachsenhausen, Frankfurt/Main, Germany

P457: Rapid faecal calprotectin test and symptom index for monitoring the disease activity in colonic IBDECCO '17 Barcelona
Year: 2017
Authors:

Puolanne A.-M.*1, Kolho K.-L.2, Färkkilä M.1

1Helsinki University Hospital, Department of Gastroenterology, Helsinki, Finland 2Helsinki University Hospital for Children and Adolescents, Helsinki, Finland

P458: Sleep problems in inflammatory bowel disease; When bed becomes a battlegroundECCO '17 Barcelona
Year: 2017
Authors:

Green A.*1, Beale A.2, Fraser A.3, Potokar J.3, Durrant C.1, Barnes M.1

1University of Bristol, Department of Social Medicine, Bristol, United Kingdom 2Bristol Royal Infirmary, Gastroenterology, Bristol, United Kingdom 3Bristol Royal Infirmary, Bristol, United Kingdom

P459: Obesity in patients with an ileoanal pouch due to ulcerative colitis is not associated with an increased risk for pouchitisECCO '17 Barcelona
Year: 2017
Authors:

Pfeffer-Gik T.*1, Fishman S.1, Godny L.1, Tulchinsky H.2, Dotan I.1

1Tel Aviv Sourasky Medical Center, IBD Center Department of Gastroenterology and Liver Diseases, Tel Aviv, Israel 2Tel Aviv Sourasky Medical Center, Proctology Unit, Department of Surgery, Tel Aviv, Israel

P460: Early use of therapeutic drug monitoring to individualize infliximab therapy in paediatric IBD: a multicentre prospective COHORT studyECCO '17 Barcelona
Year: 2017
Authors:

Crowley E.*1, Carman N.1, Arpino V.1, Frost K.1, Ricciuto A.1, Sherlock M.2, Critch J.3, Mack D.4, Benchimol E.5, Jacobson K.6, Lawrence S.6, deBruyn J.7, El-Matary W.8, Otley A.9, Huynh H.10, Church P.1, Walters T.1, Griffiths A.1

1Hospital for Sick Children, Division of Gastroenterology, Hepatology and Nutrition, Department of Paediatrics, Toronto, Canada 2McMaster Children's Hospital, Hamilton Health Sciences, Division of Gastroenterology & Nutrition, Hamilton, Canada 3Memorial University of Newfoundland, Division of Gastroenterology, Janeway Children's Health and Rehabilitation Centre, St. John's, Canada 4Children's Hospital of Eastern Ontario IBD Centre, University of Ottawa, Department of Pediatrics, Ottawa, Canada 5University of Ottawa, Children's Hospital of Eastern Ontario IBD Centre, Department of Pediatrics, Ottawa, Canada 6B.C. Children's Hospital, Division of Gastroenterology, Vancouver, Canada 7Faculty of Medicine, University of Calgary, Alberta Children's Hospital, Division of Pediatric Gastroenterology, Department of Pediatrics, Alberta, Canada 8Max Rady College of Medicine, University of Manitoba, Section of Gastroenterology, Department of Pediatrics, Manitoba, Canada 9IWK Health Centre, Department of Pediatrics, Dalhousie University, 5980 University Avenue, Division of Gastroenterology & Nutrition, Halifax, Canada 10Department of Pediatrics, University of Alberta, Edmonton, Edmonton, Canada

P461: Comparison of efficacy of different oral 5-aminosalicylic acid doses for maintenance of remission in ulcerative colitis: a systematic review and meta-analysisECCO '17 Barcelona
Year: 2017
Authors:

Choi C.H.*1, Kim Y.S.2, Moon W.3, Lee B.I.4, Kim E.S.5, Jung Y.6, Park D.I.7, Yoon Y.S.8, Lee H.9, Han D.S.10

1Chung-Ang University College of Medicine, Internal Medicine, Seoul, South Korea 2Seoul Paik Hospital, Inje University College of Medicine, Internal Medicine, Seoul, South Korea 3Kosin University College of Medicine, Internal Medicine, Busan, South Korea 4The Catholic University of Korea College of Medicine, Internal Medicine, Seoul, South Korea 5Kyungpook National University School of Medicine, Internal Medicine, Daegu, South Korea 6Soonchunhyang University College of Medicine, Internal Medicine, Cheonan, South Korea 7Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Internal Medicine, Seoul, South Korea 8Asan Medical Center, University of Ulsan College of Medicine, Surgery, Seoul, South Korea 9Seoul National University Bundang Hospital, Center for Preventive Medicine and Public Health, Seongnam, South Korea 10Hanyang University College of Medicine, Internal Medicine, Guri, South Korea

P462: Long-term outcomes of anti-TNF therapy discontinuation in patients with penetrating Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Gompertz M., Ricart E., Ordás I., Alfaro I., Lόpez A., Gallego M., Barastegui R., Giner A., Vara A., Masamunt M., Panés J.

Hospital Clinic Barcelona, Department of Gastroenterology, Barcelona, Spain

P463: Recurrence of Crohn's disease after the first surgical interventionECCO '17 Barcelona
Year: 2017
Authors:

Pontes García A.1, Gallardo Valverde J.M.*2, Iglesias Flores E.3, García Sanchez V.3, Díaz Lόpez C.2, Martínez Dueñas J.L.2, Medina J.2, Navarro E.2, Torres E.2, Gόmez Barbadillo J.2

1Universidad de Cόrdoba, Cόrdoba, Spain 2Universidad de Cόrdoba, Cirugía General, Cόrdoba, Spain 3Universidad de Cόrdoba, Digestivo del HURS, Cόrdoba, Spain

P464: Recurrence of ulcerative colitis during pregnancy in patients who became pregnant during remissionECCO '17 Barcelona
Year: 2017
Authors:

Ito A.*1, Murasugi S.2, Kashiwagi H.2, Hara T.2, Omori T.1, Yonezawa M.1, Iizuka B.1, Tokushige K.2

1Tokyo Women's Medical University, Department of Gastroenterology, Tokyo, Japan 2Tokyo Women's Medical Univercity, Tokyo, Japan

P465: Efficacy of ustekinumab for induction and maintenance of histological healing in patients with Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Li K.*1, Chan D.1, Pollack P.1, Jacobstein D.1, Brodmerkel C.1, Gasink C.1, Feagan B.G.2, Sandborn W.3, Rutgeerts P.4, De Hertogh G.5

1Janssen Research & Development, LLC, Spring House, United States 2Robarts Clinical Trials, Robarts Research Institute, Western University, London, Ont, Canada 3University of California San Diego, La Jolla, United States 4University Hospital, Gasthuisberg, Leuven, Belgium 5University Hospital Gasthuisberg, Leuven, Belgium

P466: Real world effectiveness of vedolizumab over one year in inflammatory bowel disease: a meta-analysisECCO '17 Barcelona
Year: 2017
Authors:

Schreiber S.1, Dignass A.*2, Peyrin-Biroulet L.3, Hather G.4, Demuth D.5, Khalid J.M.6, Loftus E.V.7

1University Hospital Schleswig-Holstein, Institute for Clinical Molecular Biology, Kiel, Germany 2Agaplesion Markus Hospital, Department of Medicine 1, Frankfurt/Main, Germany 3Nancy University Hospital, Dpt. Gastroenterology, Vandoeuvre, France 4Takeda Development Center, Stats Innovation, Massachusetts, United Kingdom 5Takeda Development Center Europe Ltd, Evidence and Value Generation, London, United Kingdom 6Takeda Development Centre Europe Ltd, Evidence and Value Generation, London, United Kingdom 7Mayo Clinic College of Medicine, Gastroenterology and Hepatology, Minnesota, United Kingdom

P467: Maintenance of quality of life improvement in a phase 3 study of tofacitinib for patients with moderately to severely active ulcerative colitisECCO '17 Barcelona
Year: 2017
Authors:

Panés J.*1, Rubin D.T.2, Vermeire S.3, Lindsay J.O.4, Sands B.E.5, Su C.6, Friedman G.6, Zhang H.6, Kayhan C.6, Manuchehri A.7, Healey P.8

1Hospital Clinic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain 2The University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, IL, United States 3Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium 4Centre for Immunobiology, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom 5Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, United States 6Pfizer Inc, Collegeville, PA, United States 7Pfizer Ltd, Tadworth, United Kingdom 8Pfizer Inc, Groton, CT, United States

P468: Etrolizumab treatment improves histological activity as assessed by the Robarts histopathology indexECCO '17 Barcelona
Year: 2017
Authors:

Feagan B.G.1, De Hertogh G.2, Peyrin-Biroulet L.3, Rubin D.T.4, Maciuca R.5, McBride J.5, Arulmani U.*5, Scherl A.5

1University of Western Ontario, London, Canada 2University of Leuven, Leuven, Belgium 3Université de Lorraine, Vandœuvre-lès-Nancy, France 4University of Chicago Medicine, Chicago, United States 5Genentech, South San Francisco, United States

P469: Safety, tolerability, and pharmacokinetics of the intestine-restricted oral pan-Janus kinase inhibitor TD-1473 after single and multiple oral doses in healthy subjectsECCO '17 Barcelona
Year: 2017
Authors:

Ferslew B.*1, Sherman C.2, Nguyen D.3, Graham R.1

1Theravance Biopharma, Clinical Pharmacology and DMPK, South San Francisco, United States 2Theravance Biopharma, Biostatistics, South San Francisco, United States 3Theravance Biopharma, Clinical Development, South San Francisco, United States

P470: Comparative effectiveness analysis of flares, hospitalisations, and corticosteroid use among biologic naïve patients with inflammatory bowel disease within 12 months of initiation of vedolizumab or infliximabECCO '17 Barcelona
Year: 2017
Authors:

Alam N.1, Raluy-Callado M.1, Gardstein B.2, Curtis R.3, Khalid J.M.*3

1Evidera, London, United Kingdom 2Evidera, Waltham, United States 3Takeda Development Centre Europe Ltd., London, United Kingdom

P471: Efficacy and safety of switching from reference infliximab to biosimilar infliximab in patients with inflammatory bowel disease: first French experienceECCO '17 Barcelona
Year: 2017
Authors:

Soret P.-A.*1,2, Prieux-Klotz C.1, Avouac J.3, Molto A.3, Dior M.1, Brieau B.1, Dreanic J.1, Camus M.1, Barret M.1, Coriat R.1, Conort O.4, Chast F.4, Goulvestre C.5, Le Jeunne C.6, Dougados M.3, Nahon S.2, Chaussade S.1, Abitbol V.1

1Cochin Hospital, Department of Gastroenterology, Paris, France 2Le Raincy-Montfermeil Hospital, Department of Gastroenterology, Montfermeil, France 3Cochin Hospital, Department of Rheumatology, Paris, France 4Cochin Hospital, Department of Pharmacy, Paris, France 5Cochin Hospital, Department of Biology, Paris, France 6Cochin Hospital, Department of Internal Medicine, Paris, France

P472: Original and biosimilar infliximab: Are they two faces of the same coin? The experience from a pioneer European centerECCO '17 Barcelona
Year: 2017
Authors:

Cúrdia Gonçalves T.*1, Monteiro S.1, Dias de Castro F.1, Moreira M.J.1, Cotter J.1,2,3

1Hospital da Senhora da Oliveira, Gastroenterology, Guimarães, Portugal 2University of Minho, Life and Health Sciences Research Institute, School of Medicine, Braga, Portugal 3ICVS/3B's, PT Government Associate Laboratory, Braga/Guimarães, Portugal

P473: How to monitor the withdrawal of maintenance treatment with azathioprine in IBD patients with deep remission: results from a prospective study on multiple non invasive testsECCO '17 Barcelona
Year: 2017
Authors:

Cassinotti A.*1, Massari A.1, Carmagnola S.1, Molteni P.1, Fociani P.2, Ardizzone S.1

1ASST Fatebenefratelli Sacco, Luigi Sacco University Hospital, Gastroenterology Unit, Milan, Italy 2ASST Fatebenefratelli Sacco, Luigi Sacco University Hospital, Pathology Unit, Milan, Italy

P474: An enzyme-linked immunosorbent assay for therapeutic drug monitoring of vedolizumabECCO '17 Barcelona
Year: 2017
Authors:

Berger C.1, Semmler J.1, Ruppert J.1, Schulze H.2, Armbruster F.-P.1, Dignass A.2,3, Stein J.*3,4

1Immundiagnostik AG, Bensheim, Germany 2Agaplesion Markus Krankenhaus, Frankfurt/Main, Germany 3Interdisciplinary Crohn Colitis Centre Rhein-Main, Frankfurt/Main, Germany 4DGD Clinics Sachsenhausen, Frankfurt/Main, Germany